Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.

ABSTRACT:

Background

Neoadjuvant chemotherapy (NACT) is the mainstay of treatment of stages II and III triple-negative breast cancer (TNBC). This study aims to evaluate if the addition of carboplatin to NACT is associated with an increase in the pathological complete response (pCR) rates in TNBC.

Methods

We conducted an open-label phase II randomized clinical trial in a single center in Brazil. Patients with stage II and III TNBC were randomized to receive standard NACT with or without carboplatin. All the patients received doxorubicin (60 mg/m²) plus cyclophosphamide (600 mg/m²) both intravenously (i.v.) q21 days for four cycles. Patients were then randomized for additional treatment with weekly (wk) paclitaxel (80 mg/m² i.v., for 12 cycles) plus wk c

SUBMITTER: de Padua Souza C 

PROVIDER: S-EPMC10504209 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature